Poster
63
(#63) Persistence to Cariprazine Versus Other Atypical Antipsychotics in Real-World Treatment of Bipolar I Disorder and Adjunctive Treatment of Major Depressive Disorder
Psych Congress 2025
Abstract: There is limited evidence on treatment persistence among atypical antipsychotics (AAs) used for bipolar I (BP-I) disorder and as adjunctive treatment for major depressive disorder (MDD). This study evaluated real-world persistence to cariprazine compared with other AAs in BP-I or MDD.
This retrospective study identified commercially insured adults with BP-I or MDD in the Merative™ MarketScan® Database (01/2016─03/2023) with ≥2 dispensings of cariprazine or AA comparator (aripiprazole or brexpiprazole). AAs were used adjunctively for MDD analysis. For each pairwise comparison, baseline characteristics between cohorts were balanced using inverse probability of treatment weighting. Kaplan-Meier analyses assessed persistence (>60-day gap defined non-persistence) among AAs; comparisons used hazard ratios from Cox proportional hazards models.
Among BP-I patients, median persistence was 270 days for cariprazine (n=1,296) and 207 days for aripiprazole (n=2,524), with significantly higher persistence with cariprazine vs aripiprazole at 12mo (39.6% vs 34.0%; HR:1.20, P.001]) and 24mo (24.4% vs 17.7%; HR:1.21, P.001). Among MDD patients, median persistence was 232 days for cariprazine (n=1,547) and 215 days for aripiprazole (n=22,566), with significantly higher persistence with cariprazine vs aripiprazole at 12mo (38.4% vs 34.7%; HR:1.09, P=.009]) and 24mo (23.5% vs 19.3%; HR:1.11, P=.001). In the MDD cariprazine vs brexpiprazole comparison, median persistence was 247 days for cariprazine (n=2,003) and 222 days for brexpiprazole (n=5,409), with persistence significantly higher to cariprazine vs brexpiprazole at 12mo (39.5% vs 36.7%; HR:1.08, P=.029) and 24mo (24.4% vs 21.1%; HR:1.09, P=.007).
In this real-world claims-based study, cariprazine demonstrated significantly higher persistence than aripiprazole (BP-I and MDD) and brexpiprazole (MDD).
Short Description: Atypical antipsychotics (AAs) are used for bipolar I (BP-I) disorder and as adjunctive treatment in major depressive disorder (MDD). Poor treatment persistence in psychiatry can lead to negative outcomes. This study evaluated real-world persistence to cariprazine compared with other AAs in BP-I or MDD patients. Patients with BP-I had significantly higher persistence to cariprazine compared with aripiprazole and patients with MDD had significantly higher persistence to adjunctive cariprazine compared with adjunctive aripiprazole or brexpiprazole.
Name of Sponsoring Organization(s): AbbVie Inc.
This retrospective study identified commercially insured adults with BP-I or MDD in the Merative™ MarketScan® Database (01/2016─03/2023) with ≥2 dispensings of cariprazine or AA comparator (aripiprazole or brexpiprazole). AAs were used adjunctively for MDD analysis. For each pairwise comparison, baseline characteristics between cohorts were balanced using inverse probability of treatment weighting. Kaplan-Meier analyses assessed persistence (>60-day gap defined non-persistence) among AAs; comparisons used hazard ratios from Cox proportional hazards models.
Among BP-I patients, median persistence was 270 days for cariprazine (n=1,296) and 207 days for aripiprazole (n=2,524), with significantly higher persistence with cariprazine vs aripiprazole at 12mo (39.6% vs 34.0%; HR:1.20, P.001]) and 24mo (24.4% vs 17.7%; HR:1.21, P.001). Among MDD patients, median persistence was 232 days for cariprazine (n=1,547) and 215 days for aripiprazole (n=22,566), with significantly higher persistence with cariprazine vs aripiprazole at 12mo (38.4% vs 34.7%; HR:1.09, P=.009]) and 24mo (23.5% vs 19.3%; HR:1.11, P=.001). In the MDD cariprazine vs brexpiprazole comparison, median persistence was 247 days for cariprazine (n=2,003) and 222 days for brexpiprazole (n=5,409), with persistence significantly higher to cariprazine vs brexpiprazole at 12mo (39.5% vs 36.7%; HR:1.08, P=.029) and 24mo (24.4% vs 21.1%; HR:1.09, P=.007).
In this real-world claims-based study, cariprazine demonstrated significantly higher persistence than aripiprazole (BP-I and MDD) and brexpiprazole (MDD).
Short Description: Atypical antipsychotics (AAs) are used for bipolar I (BP-I) disorder and as adjunctive treatment in major depressive disorder (MDD). Poor treatment persistence in psychiatry can lead to negative outcomes. This study evaluated real-world persistence to cariprazine compared with other AAs in BP-I or MDD patients. Patients with BP-I had significantly higher persistence to cariprazine compared with aripiprazole and patients with MDD had significantly higher persistence to adjunctive cariprazine compared with adjunctive aripiprazole or brexpiprazole.
Name of Sponsoring Organization(s): AbbVie Inc.
